Want to see TSE:ENBI.X full AI Analyst Report?
ENBI.X Stock Chart & Stats
C$0.06
C$0.00(0.00%)
At close: 4:00 PM EDT
C$0.06
C$0.00(0.00%)
Day’s Range― - ―
52-Week RangeC$0.05 - C$0.12
Previous CloseN/A
Volume18.00K
Average Volume (3M)1.32K
Market Cap
C$831.54K
Enterprise ValueC$1.06
Total Cash (Recent Filing)C$321.83K
Total Debt (Recent Filing)C$0.00
Price to Earnings (P/E)―
Beta2.85
Next Earnings
Oct 22, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding13,858,926
10 Day Avg. Volume1,950
30 Day Avg. Volume1,320
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)3.72
Price to Sales (P/S)0.00
P/FCF Ratio-3.83
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt-Free Balance SheetA debt-free balance sheet reduces fixed financial obligations and interest pressure, giving the company more flexibility while it funds development. This does not remove operating risk, but it lowers solvency pressure compared with a similarly loss-making biotechnology company carrying significant borrowings.
Reduced Loss SeverityThe substantial reduction in losses from the 2021–2022 extremes indicates some improvement in financial discipline or cost structure. If maintained, lower losses could extend available resources and reduce the scale of external funding required while the company advances its development programs.
Focused Therapeutic DevelopmentA focused biotechnology strategy around psychedelic-assisted therapies gives the company a clear development direction rather than a broad, unfocused platform. Work on drug candidates, clinical research, and regulatory preparation aligns its activities with a defined path toward potential medical use.
Bears Say
No Recent RevenueZero recent revenue shows that the company has not yet established a commercial income stream to support ongoing operations. Without recurring product or service revenue, progress remains dependent on advancing candidates successfully and securing additional funding over the next several quarters.
Persistent UnprofitabilityRecurring operating and net losses indicate that the current business model has not reached sustainable profitability. Continued losses can erode the capital base, restrict internal reinvestment, and leave future value creation dependent on successful development and eventual commercialization.
Ongoing Cash BurnPersistent negative operating and free cash flow means the company is consuming cash rather than funding development internally. The renewed deterioration in 2024 and continued negative flow in 2025 increase reliance on external capital and could constrain research progress if funding becomes less available.
Entheon Biomedical News
ENBI.X FAQ
What was Entheon Biomedical’s price range in the past 12 months?
Entheon Biomedical lowest stock price was C$0.05 and its highest was C$0.12 in the past 12 months.
What is Entheon Biomedical’s market cap?
Entheon Biomedical’s market cap is C$831.54K.
When is Entheon Biomedical’s upcoming earnings report date?
Entheon Biomedical’s upcoming earnings report date is Oct 22, 2026 which is in 46 days.
How were Entheon Biomedical’s earnings last quarter?
Entheon Biomedical released its earnings results on Jul 20, 2026. The company reported C$0.018 earnings per share for the quarter.
Is Entheon Biomedical overvalued?
According to Wall Street analysts Entheon Biomedical’s price is currently Overvalued.
Does Entheon Biomedical pay dividends?
Entheon Biomedical does not currently pay dividends.
What is Entheon Biomedical’s EPS estimate?
Entheon Biomedical’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Entheon Biomedical have?
Entheon Biomedical has 13,858,926 shares outstanding.
What happened to Entheon Biomedical’s price movement after its last earnings report?
Entheon Biomedical reported an EPS of C$0.018 in its last earnings report. Following the earnings report the stock price went down -14.286%.
Which hedge fund is a major shareholder of Entheon Biomedical?
Currently, no hedge funds are holding shares in TSE:ENBI.X
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Entheon Biomedical
Entheon Biomedical Corp. operates as a biotechnology research and drug development company. It engages in developing and commercializing various N,N-dimethyltryptamine based psychedelic therapeutic products for treating addiction and substance use disorders. The company serves physicians, clinics, and licensed psychiatrists in Canada, the United States, and European Union. Entheon Biomedical Corp. is headquartered in Vancouver, Canada.
Technical Analysis
BetterLife Pharma
―
HAVN Life Sciences
―
MYND Life Sciences
―
Universal Ibogaine Inc
―
Mindbio Therapeutics Corp.
―